Form 4: Agios Pharmaceuticals Director Rahul Ballal Executes Stock Options and Sells Shares

Director Rahul Ballal exercised stock options and sold shares of Agios Pharmaceuticals (AGIO) on November 7th and 8th, 2024, under a pre-arranged trading plan.

Summary

• Rahul Ballal, a director of Agios Pharmaceuticals, executed stock options to acquire 10,000 shares on both November 7th and 8th, 2024, at a price of $25.99 per share.
• Concurrently, Ballal sold shares of AGIO on the same days through multiple transactions at varying prices.
• On November 7th, 8,132 shares were sold at an average price of $53.32 and 1,868 shares were sold at an average price of $54.41.
• On November 8th, the sales included 3,571 shares at an average price of $57.24, 4,929 shares at an average price of $58.57, and 1,500 shares at an average price of $59.21.
• All transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Ballal directly owns 7,992 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the director's confidence in the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can reassure investors that the sales were not based on insider information.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the increased supply of shares in the market, but the pre-planned nature of the sales mitigates concerns about insider information.

Key Dates